In this post I link to and excerpt from Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis [PubMed Abstract] [Full Text HTML] [Full Text PDF]. J Allergy Clin Immunol. 2011 Apr;127(4):927-34.
The above article has been cited by nine papers in PubMed.
Here are excerpts:
Background: In clinical trials, only about 60% of subjects
report an excellent response to intranasal steroids, suggesting a
need to add therapies to intranasal steroids to provide
Objective: To determine whether the combination of fluticasone
furoate and oxymetazoline is more efficacious than either agent
alone, and to determine whether rhinitis medicamentosa
develops after treatment.
Methods: We performed a double-blind, double-dummy,
randomized, placebo-controlled parallel study. Sixty patients
with perennial allergy were randomized to 4 weeks of oncea-night treatment with fluticasone furoate, oxymetazoline
hydrochloride, the combination, or placebo. They were
monitored during treatment and for 2 weeks posttreatment.
Results: The total nasal symptom score over the 4 weeks of
treatment was lower with the combination (median, 143; range,
30-316) compared with treatment with placebo (262; 116-358)
and oxymetazoline alone (219; 78-385; ANOVA, P 5 .04). When
acoustic rhinometry was compared between the groups at the end of 4 weeks of treatment, the combination resulted in significantly higher nasal volume (mean 1 SEM, 15.8 1 1.1 mL; P < .03) compared with both placebo (12.1 1 0.9 mL) and oxymetazoline (12.4 1 0.8 mL) alone. The quality of life data showed no significant differences among the groups. Peak flow showed a nonsignificant improvement with the groups on fluticasone furoate. There was no evidence of rhinitis medicamentosa.
Conclusion: The addition of oxymetazoline adds to the
effectiveness of fluticasone furoate in the treatment of perennial
allergic rhinitis. The lack of development of rhinitis
medicamentosa suggests the need for a large multicenter study
to develop a once-a-day combination of an intranasal steroid
and a long-acting topical decongestant. (J Allergy Clin Immunol
Key words: Allergic rhinitis, perennial, fluticasone furoate, oxymetazoline, clinical trial, rhinitis medicamentosa
FF: Fluticasone furoate
FF/OXY: Fluticasone furoate/oxymetazoline hydrochloride
NPIF: Nasal peak inspiratory flow
OXY: Oxymetazoline hydrochloride
RQLQ: Rhinitis Quality of Life Questionnaire